Papillomatosis cutis arising on an immuno-compromised district due to paraplegia

Adone Baroni, Eleonora Ruocco(University of Campania "Luigi Vanvitelli"), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Rosa Di Maio(University of Campania "Luigi Vanvitelli"), Tonia Nuzzo(University of Campania "Luigi Vanvitelli"), Vincenzo Ruocco(Tel Aviv University)
British Journal of Dermatology
April 29, 2010
10.1111/j.1365-2133.2010.09833.x
Cited by 15

Related Papers

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780
Interleukin-12: Biological Properties and Clinical Application
|Clinical Cancer Research|2007|606
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
|The Lancet Oncology|2020|530
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
|The Lancet Oncology|2017|501